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Kagami-Ogata syndrome (KOS14) and Temple syndrome (TS14) are two disorders associated 
with reciprocal alterations within the chr14q32 imprinted domain. Here we present a work-




We analysed DNA from the KOS14 index case and parents using methylation-sensitive ligation 
mediated probe amplification and methylation pyrosequencing. The extent of the deletion 
was mapped using SNP arrays. PGT was performed in trophectoderm samples in order to 
identify unaffected embryos. Samples were amplified using multiple displacement 
amplification, followed by genome-wide SNP genotyping to determine the at-risk haplotype 
and next generation sequencing to determine aneuploidies.  
 
Results: 
A fully methylated pattern at the normally paternally methylated IG-DMR and MEG3 DMR in 
the KOS14 proband, accompanied by an unmethylated profile in the TS14 mother was 
consistent with maternal and paternal transmission of a deletion, respectively. Further 
analysis revealed a 108 kb deletion in both cases. The inheritance of the deletion on different 
parental alleles was consistent with the opposing phenotypes. In vitro fertilization with 
intracytoplasmatic sperm injection and PGT were used  to screen for deletion status and to 
transfer an unaffected embryo in this couple. A single euploid-unaffected embryo was 
identified resulting in a healthy baby born. 
 
Discussion: 
We identify a microdeletion responsible for multi-generation KOS14 and TS14 within a single 
family where carriers have a 50% risk of transmitting the deletion to their offspring. We show 




















Disturbances of the chromosome 14q32 (chr14q32) imprinted domain are associated with 
both Kagami-Ogata syndrome (KOS14) (OMIM 608149) and Temple syndrome (TS14)(OMIM 
616222), depending on the parental-origin of the aberration. Historically these two syndromes 
have been known as paternal uniparental disomy 14 (UPD(14)pat)-like syndrome and 
UPD(14)mat-like syndrome, respectively, as these are the most frequent genetic causes1,2. 
However, detailed molecular characterisation in patients without UPD has identified subtle 
deletions and imprinting defects in a subset of probands3,4. Therefore, both KOS14 and TS14 
are recognised congenital diseases that belong to the group of imprinting disorders (IDs) that 
result from the abnormal dosage of imprinted genes. Imprinted genes are typified by their 
parent-of-origin monoallelic expression; in other words, they are only expressed from the 
maternally or paternally inherited copy, but not both. The control of this monoallelic 
expression is regulated by the interplay between different epigenetic mechanisms, but is 
largely dependent upon differentially methylated regions (DMRs) that orchestrate 
coordinated transcriptional repression5.  
 The human chr14q32 locus harbours a cluster of imprinted genes within a 680 kb 
interval that includes the paternally expressed DLK1 and RTL1 transcripts, and the maternally 
expressed MEG3/GTL2, RTL1-antisense, MEG8 and a large cluster of snoRNA (SNORD113-114) 
and micoRNAs (miR493-miR154)6. The parental origin-dependent expression is coordinated 
by the germline-derived DLK1-MEG3 intergenic DMR (IG-DMR; MEG3/DLK1:IG-DMR)7  and the 
somatically acquired secondary MEG3 DMR (MEG3:TSS-DMR), both of which are methylated 
on the paternal allele8. Two additional intergenic DMRs have been identified within the locus 
associated with MEG8 (MEG8:Int2-DMR) and DLK1 (DLK1:Int1-DMR)9,10, both of which are 
methylated on the maternal chromosome following fertilization, although their functions are 
not yet known. 
 Hypermethylation of the IG-DMR and MEG3 DMR, maternal microdeletions and 
UPD(14)pat are associated with the KOS14 phenotype that includes facial abnormalities, small 
bell-shaped thorax with coat-hanger ribs, abdominal wall defects, placentomegaly, 
polyhydramnios and severe intellectual disability11. In contrast hypomethylation of IG-DMR 
and MEG3 DMR, paternal microdeletions and UPD(14)mat cause TS14 which is characterised 
by prenatal and postnatal growth restriction, hypotonia, feeding difficulties, truncal obesity 
and precocious puberty4, 12. To date, ~60% of KOS14 and TS14 cases are caused by UPD14, 
while microdeletions involving IG-DMR and MEG3 DMRs account for ~20% and ~10% of cases, 
respectively. Imprinting defects affecting the paternally methylated DMRs occurs in ~20% of 
cases for both diseases 12. Because of the non-specific phenotypic features associated with 
TS14, a small proportion of idiopathic cases maybe associated with a differential diagnosis, 
such as Silver-Russell syndrome (SRS)11, 13.  
Preimplantation genetic testing, as defined in 2017 by Zegers-Hochschild et. al., is a 
test performed to analyze the DNA from oocytes (polar bodies) or embryos (cleavage stage or 
blastocyst) for HLA typing or for determining genetic abnormalities14. Typically, single gene 
disorders and/or structural chromosome aberrations are detected via PCR methodologies or 
next generation techniques (NGS). Biopsy can be performed at different embryo 
developmental stages. Thus, polar body analysis can be performed on mature oocytes and/or 
the zygote, blastomere analysis can be accomplished at the cleavage stage and trophectoderm 
analysis at the blastocyst stage. In recent years a growing trend has been observed for laser 
trophectoderm biopsy in assisted reproduction techniques (ART) to the detriment of the other 
two strategies15. For the detection of unaffected-euploid embryos whole genome 
amplification from trophectoderm samples can be performed. The amplification products are 
subjected to genome-wide single nucleotide polymorphisms (SNPs) array and linkage analysis, 
for example using Karyomapping16. This consists of analyzing hundreds to thousands of SNPs 
scattered throughout the genome of the parents, their embryos and a reference allowing the 
identification of the parental origin of the chromosomes. Analysis of results obtained from the 
parents and a reference (a relative with known genetic status, usually a sibling or a 
progenitor), allows for the identification of the at-risk chromosome. Knowing the haplotype 
at risk, it is possible to track which embryos have inherited the at-risk chromosome (or SNP 
combination at risk) or its normal counterpart. Thus, transfer of embryos carrying the 
condition can be avoided.  
Testing for aneuploidy in the embryos of in vitro fertilization (IVF) patients and the 
subsequent transfer of those that are chromosomally normal has been shown to improve the 
ongoing pregnancy rate17,18. Genome-wide SNP analysis allows Karyomapping to support copy 
number variants (CNV) and, therefore, to detect some trisomies and/or monosomies. 
However, not all the aneuploidy events can be detected and comprehensively confirmation of 
euploidy requires NGS analysis. 
 Here, we report a family with a 108 Kb deletion spanning the IG-DMR and MEG3 DMR 
interval that produces KOS14 on maternal transmission and TS14 when located on the 
paternally inherited chromosome. The exact size and location of this deletion indicates it is 
the smallest microdeletion associated with these IDs within a single family and our detailed 
description of its molecular and clinical consequences allowed for the design and successful 




Bisulphite treatment of 1ug of DNA was performed with the EZ DNA methylation-Gold spin 
columns (Zymo Research), following the manufacturer’s protocol. Control DNAs from patients 
carrying UPD(14)pat and UPD(14)mat were used to detect extreme methylation values at the 
imprinted DMRs assessed. Pyrosequencing was selected for the quantitative assessment of 
DNA methylation at the IG-DMR, MEG3 DMR, DLK1 DMR and MEG8 DMRs as previously 
described9,10,19,20(see Supplementary Table 1 for primer sequences). Bisulphite PCR was 
performed with one primer being biotinylated. Immobilization of the PCR products for 
purification was achieved by streptavidin-coated sepharose beads (Qiagen) with the use of 
the PyroMark Q24 Vacuum Prep Workstation according to the manufacturer’s instructions.  
 
Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) 
Gene dosage and methylation analyses of the chromosomal region 14q32 including the IG-
DMR and MEG3 DMR were carried out using the SALSA MLPA Kit ME032-A1 (MRC Holland, 
Amsterdam, The Netherlands) according to the manufacturer’s manual. Amplification 
products were analysed on an ABI3500 capillary sequencer (Applied Biosystems) followed by 




Saliva-derived genomic DNA from the index case was quantified using Nanodrop1000 
spectrophotomer (Thermofisher) and Qubit (Thermofisher). Chromosomal microarray 
analysis was performed with the genome-wide scan of 850,000 tag SNPs (Illumina Infinum 
CutoSNP-850k BeadChIP) following standard laboratory procedures. Copy-number variations 
were determined using the Chromosome Viewer tool contained in the Genome Studio 
package (Illumina). In Chromosome Viewer, gene call score <0.15 at a locus were considered 
“no calls”. In addition, all allele frequency analysis was applied for all SNPs. 
 
Long-range PCR 
PCR products were generated from DNA samples of the KOS14 index case using Immolase 
DNA Taq polymerase (Bioline) and staggered PCR primers. An amplicon was obtained using 
C4F-ACCGGAGTTCCTTTCAGAGACA and TR3-GGTTCAGGCAGGGTACAGGACAT. The resulting 
PCR product was subject to Sanger sequencing in both directions using BigDye Terminator v3.1 
kit (Thermofisher) and run on ABI 3730 DNA 48-capillary sequencer. The resulting 
electropherograms were analysed in Sequencher and subject to BLAST in the UCSC genome 
browser. 
 
Embryo biopsy and tubing 
Following standard assisted reproductive techniques, laser mediated trophectoderm biopsy 
was carried out and 4 to 7 cells on average were obtained from each embryo. After biopsy, 
embryos were vitrified for future transfer. Biopsied cells were washed and collected into 
sterile RNAse and DNAse free PCR tubes.  
 
PGT-M for Imprinting disorder 
Preimplantation Genetic Testing for monogenic disorders (PGT-M) was carried out using 
Karyomapping. This is a genome-wide SNP genotyping technique that allows for both the 
study of the imprinting disorder though linkage analysis and the identification of CNVs.  
 
Pre-test analysis 
Prior to IVF-Intracytoplasmic sperm injection (ICSI)-PGT cycle, 400 ng of genomic DNA samples 
from parents and the KOS14 index case were investigated in order to confirm the presence of 
informative SNPs inside the microdeletion and the flanking regions (2.0 Mb) through 
Karyomapping technique. This method involved the use of the Illumina Infinium 
HumanKaryomap-12 DNA analysis kit, according to the manufacturer’s instructions.  
 Bead array datasets were then imported into dedicated software (BlueFuse Multi, 
Illumina), which assisted with the visualization and interpretation of the data obtained with 
Karyomapping  cases. The outcome of the laboratory protocol is a set of genotype calls for 
each SNP on the array, depicted at four values: AA, AB, BB or NC (no call), where A represents 
the nucleotides adenine (A) and thymine (T) and B represents the nucleotides guanine (G) and 
cytosine (C) in the genetic sequence. We consider a SNP as informative when a genotype can 
be assigned to one of the chromosomes inherited from the mother or father (one parent must 
be heterozygous while the other is homozygous). 
 
PGT-M analysis 
Embryonic DNA was subjected to whole genome amplification using multiple displacement 
amplification (MDA) following manufacturer’s protocols (Repli-G Single cell kit, Qiagen).  
Electrophoresis was carried out to confirm that all samples and positive controls amplified 
appropriately.  
 Afterwards, 8µl of MDA amplification product from each embryo sample was 
processed with the Karyomapping technique. After scanning of the bead chip, the data was 
imported into the BlueFuse Multi software in order to phase the SNPs in the embryo in relation 
to the alleles of the KOS14 index (which will be referred to as the reference) to determine the 
parental inheritance of the haploblock at-risk.  
 Embryo and reference were referred to be in phase when they inherited the same 
chromosome and to be out of phase when they inherited a different chromosome. A 
consequence of relative phasing is that recombination events in the reference cause a change 
of phase in all corresponding embryos, and as a result the position of recombination events 
can be determined. Since allele drop-out (ADO) can result in the loss of an informative allele, 
the software classifies the analysed SNPs in two groups: key SNPs and non-key SNPs. Key SNPs 
provide strong support of the predicted phase since they contain the informative allele so ADO 
could not have affected their phasing. In contrast, non-key SNPs provide weaker support of 
the predicted phase. This group does not contain the informative allele so it is not possible to 
distinguish between homozygous genotypes from the loss of the informative allele through 
ADO. Due to the large amount of phasing data available, Karyomapping results are not 
affected by ADO and also allows for the detection of meiotic and some mitotic CNVs, as well 
as tracing the parental origin of aneuploidies.  
 
Preimplantation Genetic Testing for aneuploidies 
Since Karyomapping has not been fully validated for the purpose of aneuploidy screening, 
embryos considered to be unaffected that did not show numerical chromosomal 
abnormalities by Karyomapping were analyzed by NGS. Aliquots of the same whole-genome 
amplified trophectoderm samples were used for NGS-based technology by means of VeriSeq 
PGS Kit (Illumina, San Diego, CA, USA) on Illumina MiSeqTM System according to the 
manufacturer instructions and were analyzed by the BlueFuse Multi software (Illumina). 
 The Veriseq PGS kit uses an engineered transposome for the preparation of 
sequencing-ready libraries to tagment the input DNA. Subsequently, a limited-cycle PCR uses 
the adapter sequences to amplify the insert DNA and to add index sequences to both ends of 
the DNA. Prepared VeriSeq PGS libraries are pooled and run on the MiSeq system, where 
secondary analysis of the data is performed, demultiplexing and aligning the reads to the 
reference genome. Data obtained are imported into BlueFuse Multi Analysis software, which 
process and display the data to provide genomic profiles of each sample in a run. Whole 
chromosome aneuploidy is called automatically. The effective resolution of the assay is 20 Mb. 
The number of reads after filtering, sample overall noise score and average quality alignment 




Clinical history  
The index case was prenatally followed for omphalocele associated with severe 
polyhydramnios. At 26-weeks of gestation an amniodrainage was required to avoid premature 
delivery as the patient initiated uterine contractions and cervical shortening. The procedure 
was complicated by a placental abruption requiring an emergency caesarean section. Birth 
weight was 760 g and 5 minutes Apgar score was 8. Following birth, a silo was applied to 
contain the omphalocele and surgical correction was completed after 4 days. The newborn 
showed macroglossia with large filtrum, hypersialorrhea and a bell-shaped thorax with coat-
hanger ribs. Based on these clinical findings a diagnosis of KOS14 was suspected. The newborn 
presented respiratory and infectious complications dying at 74 days of life. 
 
Molecular genetic findings  
Methylation analysis in the KOS14 index case was performed by bisulphite PCR followed by 
pyrosequencing for the germline-derived paternally methylated IG-DMR. This revealed the 
presence of fully methylated sequences only, indicating that the patient has UPD(14)pat, a 
deletion or imprinting defects. Microsatellite analysis did not provide evidence of UPD. MS-
MLPA was used to differentiate between a deletion and an imprinting defect, which identified 
a maternally-inherited deletion (Figure 1A). Subsequent pyrosequencing and MS-MLPA 
analysis in parental samples revealed that the mother also carried the deletion but on her 
paternal inherited chromosome (Figure 1A). Using Illumina genome-wide human SNP array 
analysis, the deletion was shown to include DLK1 and the first 4 exons of MEG3 (Figure 1B). 
Long-range PCR encompassing the last known intact SNPs was used to amplify across the 
deletion, which revealed it spanned 108,762 bp (hg19 
chr14:g.101190852_101299552del)(Figure 2A, B). Sequence comparisons with the hg19 
reference genome revealed a 1 bp thymine insertion between the centromeric and telomeric 
breakpoints.  
 
Additional characterization of imprinted methylation  
The 108 kb deletion removed not only the IG-DMR but the somatically acquired paternally 
methylated MEG3 DMR and the intragenic maternally methylated DLK1 DMR. These 
observations were confirmed using pyrosequencing in DNA from the KOS14 index case and 
the mother (Figure 3; Supplementary Table 2)3. In addition to these regions, an additional post 
zygotically-acquired imprinted DMR maps to the second intron of MEG810. Although not 
contained within the deletion, this DMR presents with altered allelic methylation consistent 
with hierarchical acquisition dependent upon correct germline establishment of the IG-DMR 
(Figure 2) 21.   
 
Paternal deletion is consistent with Temple syndrome 
The methylation analysis of the paternally methylated IG-DMR and MEG3 DMR was severely 
hypomethylated in the mother’s DNA sample3(Supplementary Table 2). Subsequent clinical 
investigations revealed that she presented with several main characteristics of TS14, including 
short stature with a final adult height of 152 cm, precocious puberty at 7 years (with 
Decapeptyl GNRH agonist therapy until 13 years) and had high fasting blood sugar levels 
consistent with diabetes. Diagnosis of TS14 in adulthood is difficult because of the debilitating 
non-specific clinical features, however the phenotype observed is consistent TS14 and a lack 
of DLK1 expression4, 12. 
 
Pre-implantation genetic testing 
The recurrence risk of KOS14 in subsequent pregnancies for the mother is 50% due to the 
dominant nature of inheritance. Since the couple wished to have a family, following genetic 
counselling, pre-implantation genetic testing was performed.  
A total of 614 SNPs were assessed by the HumanKaryomap-12 BeadChip in the 
preliminary analysis of genomic DNA samples from the KOS14 index case and parents. The 
results obtained revealed the presence of 69 maternal informative SNPs (none in the 
microdeletion region, 37 in the left flanking region and 32 in the right one) and 143 paternal 
informative SNPs (5 in the deleted region, 78 in the left flanking region and 60 in the right 
one). 
Subsequently, three rounds of ovarian stimulation and ICSI resulted in 10 embryos (6 
in the first cycle, 1 in the second and 3 in the third). Following trophectoderm biopsy, embryo 
testing was performed by Karyomapping to identify embryos that carried the deletion using 
SNP phasing and subsequent NGS for the analysis of numerical chromosomal abnormalities. 
Four embryos were diagnosed as affected, two as affected and aneuploid and 3 as unaffected 
with aneuploidy (Table 1). No recombination events affected the region of interest in any of 
the analyzed embryos. A single unaffected and euploid embryo was identified and transferred 
(Figure 4). The subsequent pregnancy was unremarkable and a healthy baby boy was born at 




Here we describe a child diagnosed with KOS14 due to a maternally inherited deletion of 
14q32. The proband was noted to have several abnormalities consistent with the suspicion of 
KOS14, that was confirmed upon molecular investigations. Methylation and copy-number 
analyses determined that the deletion on the paternal chromosome was sufficient to cause 
TS14 phenotype in the proband’s mother. KOS14 is frequently associated with prematurity 
due to polyhydramnios, with a mortality rate of ~30% that invariable occurs before 4 years of 
age due to postnatal respiratory insufficiency and infection. The cases that survive beyond this 
stage always have severe developmental delay22. This syndrome, unlike most other IDs, 
warrants PGT when the molecular mechanism indicates high reoccurrence, such as 
microdeletion or UPD associated with Robertsonian translocations23. 
Upon reviewing current medical literature, characterisation of KOS14 with deletions of 
different sizes has unveiled the regulatory mechanisms associated within the 14q32 imprinted 
domain. The deletion described here is one of smallest associated with both KOS14 and TS14 
in the same family. A similar familial case resulting in both syndromes has been reported with 
deletion breakpoints in approximately similar locations (family A)3 (Supplementary  Figure 1), 
resulting in a deletion 6 bp larger. A maternally inherited 133 kb deletion has been described 
in KOS that left the DLK1 gene and IG-DMR intact, which upon paternal deletion did not result 
in TS1424. Similarly, a 8.6 Kb deletion encompassing the IG-DMR was identified in a KOS14 
case, with the mother showing some TS14-phenotypic features including short stature and 
obesity. However, the authors concluded that these clinical features were non-specific and 
appear to be irrelevant to the microdeletion8. This highlights the difficultly in diagnosing TS14 
in adulthood and a consensus is required to whether TS14 is primarily a clinical diagnosis with 
confirmation using molecular testing similar to SRS25. Overall, these finding are consistent with 
KOS14 being caused by aberrant dosage of the imprinting RTL1 gene3, 26, whilst disruption of 
DLK1 is responsible for TS14, as highlighted by a ~14 kb microdeletion that removed the DLK1 
promoter and first exon, leaving the remainder of the loci intact27.  
Underlying the mechanism associated with the KOS14 index case has allowed for the 
design of a PGT-M strategy to track the inheritance of the chromosomes involved. By using 
Karyomapping, we have been able to correctly diagnose which embryos have received the  
chromosome carrying the deletion, thus, avoiding the transfer of affected embryos. 
Karyomapping has allowed preimplantation genetic testing for monogenic diseases to be 
faster (by reducing the time for work-up), versatile (we can use the same platform for different 
diseases) and powerful (much more markers are studied compared to conventional PCR 
techniques) as well as being applied in de novo cases28. 
Genome wide haplotyping analysis also allowed us to detect some aneuploidies in the 
embryo cohort. Aneuploidy is thought to be the main reason for the failure of IVF. Detection 
of anomalies, utilizing NGS technologies, and the confirmation of the correct chromosome 
complement increases the chance of pregnancy for couples undergoing ART. The combination 
of Karyomapping and NGS is a powerful method that allowed us to transfer one unaffected-
euploid embryo that resulted in an unremarkable pregnancy and the birth of a healthy baby. 
The use of trophectoderm biopsies allows for higher technical and biological 
robustness compared to other sampling strategies. Trophectoderm biopsies allowing for the 
analysis of a larger number of cells, thus reducing the technical error (lower ADO rates) and 
biological error, while reducing the impact of mosaicism on molecular analysis. Moreover, it 
has been reported that blastomere biopsy reduces implantation rates while blastocyst 
biopsies do not 29. Interestingly, polar body (PB) biopsy has been proposed as an alternative 
to the other strategies especially in countries where embryo biopsy is prohibited for legal 
reasons30,31. However, although it should be potentially considered less invasive because it 
involves the removal of by-products of the meiotic division of the oocyte, this type of biopsy 
has many drawbacks.  For instance, analysis of PBs  provides an indirect approach, so that the 
genetic or chromosomal status of the oocyte is deduced from that of the PB. Both PBs from 
all mature oocytes and/or zygotes are needed regardless of their developmental potential and 
need to be analysed separately, increasing the workload and the cost of the procedure. Also, 
higher false-positive and negative error rates have been reported when PB biopsy is 
performed32 and it is noted that mitotic aneuploidies and chromosomal abnormalities 
originating in the sperm cannot be detected.  
Alternative PGT strategies, encompassing the recent advances in epigenetic 
technologies, include the quantification of DNA methylation in extremely low input samples. 
This has led to the suggestion that epigenetic profiling of embryo biopsies or PBs could 
complement PGT for IDs23. However, as described above, the accuracy using such methods 
would still be influenced by ADO and allelic methylation profiling at single-cell resolution is 
currently not feasible. Furthermore, despite the high methylation correlations between 
oocytes and PBs33, it must be noted that biopsies from preimplantation embryos are obtained 
during a developmental time window when the epigenome is dynamic, and whilst methylation 
at imprinted DMRs is largely resistant to this epigenetic reprogramming, it remains to be 
determined if some disparity exists. In addition, for biopsies are taken before implantation, 
somatically acquired imprinted DMRs, including at MEG3 DMR, are not established, so 
profiling such intervals could report erroneous results34. 
Although prenatal diagnosis of KOS14 has been performed before35, to the best of our 
knowledge, this is the first report of the application of PGT-M in order to avoid an IDs in the 
progeny of a microdeletion carrier. When studying IDs, it is imperative that parental 
transmission is taken into consideration, as reciprocal inheritance of a genetic anomaly may 
result in syndromes with substantially different severity. The PGT-M strategy described here 
allows for the differentiation of parental chromosome complements, thus fulfilling the 
requirement in the detection of IDs to determine the transmission of the involved 
chromosome to the offspring. Preimplantation genetic testing is only warranted for the most 
severe disorders, such as KOS14, and not TS14. With the improvements in technology and 
growing knowledge of IDs, employing PGT-M for KOS14 is an attractive alternative to prenatal 
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Figure legends 
Figure 1. Molecular characterization of the chr14q32 deletion. 
(A) MS-MLPA analysis in the KOS14 index case and maternal DNA-samples reveals a 
reciprocally inherited deletion encompassing the IG-DMR and MEG3 DMR. The upper panels 
represent copy number, while the lower panels indicate methylation profile. Note the normal 
methylation at the PLAGL1, GRB10 and MEST DMRs. (B) SNP array analysis determined the 
approximate size of the deletion in the KOS14 index case revealing loss of DLK1 and the first 4 







Figure 2. Defining the deletion breakpoints 
(A) Schematic overview of the chr14q32 imprinted domain.(B) The position of the 
breakpoints were determined by long-range PCR followed by Sanger sequencing 





















Figure 3. Methylation profiling of the KOS14 index case and parental DNA samples. 
Pyrosequencing was used to quantify methylation of CpG dinucleotides in the DLK-DMR 
(maternally methylated), IG-DMR (paternally methylated), MEG-DMR (paternally methylated) 
and the MEG8-DMR (maternally methylated). Violin plots represent the average methylation 
profiles of 15 control individuals, whereas data points are shown for the KOS14 index case 


























Figure 4. Haploblock analysis of the unaffected-euploid embryo as seen in BlueFuse 
software after analysis by Karyomapping.  F refers to father genomic DNA sample, and P1 
and P2 are the paternal chromosomes. M refers to mother genomic DNA, where M1 is the 
maternal chromosome associated to the mutant phase and M2 is the normal maternal 
chromosome. R is the reference, in this case, DNA from KOS14 index case. E3 refers to embryo 
3, non-carrier of the maternal mutant phase. The 2 Mb region of interest is highlighted in grey. 
For E3, the paternal haplotype is represented in dark blue and the maternal haplotype in dark 
red. Dots above the corresponding red/green bars represent key SNP positions and those 
below are the non-key SNP positions. Dots inside the bar are no call SNPs. 
 
Table 1. PGT results after analysis by Karyomapping and NGS. 
 
Supplementary Figure 1. Mapping the breakpoints for the KOS14 proband and that 
responsible for family A in Kagami et al., 2008. 
 
Supplementary Table 1. Primer sequences used in this study. 
 
Supplementary Table 2. Pyrosequencing results for the affected family and controls. 
TABLE 1.  
CYCLE EMBRYO 







1 AFFECTED ND NA AFFECTED NON SUITABLE 
2 AFFECTED ND NA AFFECTED NON SUITABLE 




10A AFFECTED ND NA AFFECTED 
NON 
SUITABLE 


































ND: Not detected; NA: Not analyzed. Only unaffected embryos with no detectable aneuploidies by Karyomapping were analyzed by NGS. 
 
 
 
 
